As one of your constituents, District
Activist Leader for the National Multiple Sclerosis Society and Consumer
Reviewer for the Congressionally Directed Medical Research Program’s (CDMRP)
Multiple Sclerosis Research Program (MSRP, Congress must pass final
appropriations bills for fiscal year (FY) 2017 to avoid a continuing resolution
(CR) that will endanger research funding and the future of medical progress for
chronic diseases like MS.
Each appropriations cycle is an opportunity for Congress to
adjust spending priorities and reevaluate the needs of our nation. A long-term
(more than 3 months) CR would have dangerous effects on all areas of research
and further extend the time that people with MS will wait for new therapies and
treatments. A Continuing Resolution extending current FY16 funding levels will
effectively “flat-fund” research and prevent innovative research from being
funded through the MS Congressionally Directed Medical Research Program (CDMRP)..
“Flat-funding”
actually results in a net decrease in the research accomplished by appropriated
dollars as the cost of doing research rises each year. Congress should
robustly fund medical research funding for MS, specifically the NIH and the MS
Congressionally Directed Medical Research Program.
Sincerely